The proposed acquisition offers a potentially new, differentiated best-in-class approach to address the unmet need for a broader number of patients with immuno-inflammatory diseases
The interim results of Phase 3 clinical trials conducted by CanSinoBIO demonstrated that Convidecia has an efficacy of 95.47% at preventing severe disease 14 days after single-dose vaccination.
Focused medicines company delivering strong operational performance. Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint
Going forward, the fastest-growing regions in the generic pharmaceuticals market will be South America and the Middle East, where growth will be at CAGRs of 10.1% and 9.4% respectively
According to the Russian Direct Investment Fund (RDIF), the Russian Sputnik V and Sputnik Light vaccines have proven to be highly effective against all variants of SARC-Cov-2
Market demand for significant volumes and quality of biopharma products would drive continuous manufacturing technologies
Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins
The partnership will help advance GreenLight's messenger RNA Covid-19 vaccine candidate
It is estimated that one-third of our country’s population has some form of these disorders
The loan will fund at least 667 million Covid-19 vaccine doses for an estimated 317 million people
Subscribe To Our Newsletter & Stay Updated
